September 24, 2020
Ono Pharmaceutical’s PD-1 inhibitor Opdivo (nivolumab) extended progression-free survival (PFS) as a frontline treatment of gastric cancer in a PII/III study conducted in Japan, South Korea, and Taiwan, according to latest study data presented at the European Society of Medical...read more